

Yu-Wei Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1431445/publications.pdf>

Version: 2024-02-01

37
papers

761
citations

516710

16
h-index

526287

27
g-index

37
all docs

37
docs citations

37
times ranked

1575
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. <i>Journal of Urology</i> , 2015, 194, 343-349.	0.4	109
2	Racial differences in suicide deaths after cancer diagnosis: A SEER-based analysis of 2,336,949 patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 244-244.	1.6	89
3	Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 683-690.	0.8	57
4	Association Between Travel Distance and Choice of Treatment for Prostate Cancer: Does Geography Reduce Patient Choice?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 313-317.	0.8	51
5	Prostate Brachytherapy Case Volumes by Academic and Nonacademic Practices: Implications for Future Residency Training. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 624-628.	0.8	48
6	Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?. <i>BJU International</i> , 2016, 118, 95-101.	2.5	45
7	The decreased use of brachytherapy boost for intermediate and high-risk prostate cancer despite evidence supporting its effectiveness. <i>Brachytherapy</i> , 2016, 15, 701-706.	0.5	37
8	National Trends in Admission for Aspiration Pneumonia in the United States, 2002-2012. <i>Annals of the American Thoracic Society</i> , 2017, 14, 874-879.	3.2	34
9	National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. <i>Cancer</i> , 2016, 122, 3371-3377.	4.1	27
10	National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. <i>Cancer</i> , 2016, 122, 1505-1512.	4.1	27
11	Association Between Older Age and Increasing Gleason Score. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 525-530.e3.	1.9	23
12	Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes. <i>European Urology Focus</i> , 2016, 2, 532-539.	3.1	23
13	Risk of prostate cancer mortality in men with a history of prior cancer. <i>BJU International</i> , 2016, 117, E20-8.	2.5	22
14	Travel distance and stereotactic body radiotherapy for localized prostate cancer. <i>Cancer</i> , 2018, 124, 1141-1149.	4.1	21
15	COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 155, 291-293.	2.8	19
16	Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 57.e15-57.e22.	1.6	17
17	Cost-effectiveness of Management Options for Small Renal Mass. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 484-490.	1.3	16
18	Occult High-risk Disease in Clinically Low-risk Prostate Cancer with $\geq 50\%$ Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?. <i>Urology</i> , 2016, 87, 125-132.	1.0	16

#	ARTICLE	IF	CITATIONS
19	Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 330.e19-330.e25.	1.6	13
20	Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. <i>Brachytherapy</i> , 2016, 15, 695-700.	0.5	13
21	Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. <i>American Journal of Medicine</i> , 2018, 131, 517-523.	1.5	13
22	Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 421-428.	4.9	10
23	Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 563-569.e3.	1.9	7
24	The association between race and venous thromboembolism risk after initiation of chemotherapy: An analysis of the <sc>SAVE</sc>â€œ<sc>ONCO</sc> trial control arm. <i>American Journal of Hematology</i> , 2017, 92, E101-E103.	4.1	7
25	Implications of the United States Preventive Services Task Force Recommendations on Prostate Cancer Stage Migration. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e12-e16.	1.9	6
26	Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancer. <i>Brachytherapy</i> , 2015, 14, 511-516.	0.5	4
27	The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 470.e19-470.e29.	1.6	4
28	Can pelvic lymph node dissection be omitted in intermediate-risk prostate cancer patients? A SEER-based comparative study using inverse-probability-of-treatment weighting.. <i>Journal of Clinical Oncology</i> , 2015, 33, 95-95.	1.6	2
29	Prevalence of venous thromboembolism diagnosed in emergency department visits by cancer patients and associated healthcare resource utilization in the United States. <i>American Journal of Hematology</i> , 2018, 93, E207.	4.1	1
30	Incidence and predictors of upgrading and upstaging among 10,000 contemporary patients with low-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 32-32.	1.6	0
31	Incidence and predictors of prostate cancer death in men with other prior malignancies: An analysis from SEER Database.. <i>Journal of Clinical Oncology</i> , 2015, 33, 34-34.	1.6	0
32	Determinants for no definitive therapy for early-stage non-small cell lung cancer in U.S. population.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1590-1590.	1.6	0
33	Contemporary use of lymph node dissection at nephroureterectomy in treating upper tract urothelial carcinoma: A US population-based analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15634-e15634.	1.6	0
34	Variation in national use of long-term ADT by disease aggressiveness among men with unfavorable-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 54-54.	1.6	0
35	Socioeconomic disparities in the receipt of radiation for node-positive prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 53-53.	1.6	0
36	Trends and clinico-sociodemographic determinants of stereotactic body radiotherapy use for localized prostate cancer: A National Cancer Database study.. <i>Journal of Clinical Oncology</i> , 2017, 35, e545-e545.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.. Journal of Clinical Oncology, 2017, 35, 18-18.	1.6	0